Macrocytic Anemia with Thrombocytopenia and Stage 3b CKD: Evaluation and Management
This 73-year-old patient requires immediate evaluation for vitamin B12 and folate deficiency, peripheral blood smear review with consideration for bone marrow biopsy to exclude myelodysplastic syndrome (MDS), and assessment of iron stores, given the combination of macrocytic anemia (MCV 98 fL), thrombocytopenia (112 × 10³/μL), elevated RDW (17.1%), and stage 3b chronic kidney disease (eGFR 33 mL/min/1.73 m²). 1
Primary Diagnostic Interpretation
Hematologic Abnormalities
Macrocytic anemia (MCV 98 fL, borderline high; hemoglobin 11.8 g/dL) with elevated RDW (17.1%) indicates heterogeneous red cell populations, suggesting either nutritional deficiency or bone marrow dysfunction 1.
Thrombocytopenia (112 × 10³/μL) combined with anemia raises concern for multilineage cytopenias, which warrants hematology consultation as this pattern suggests bone marrow failure syndromes or MDS rather than isolated nutritional deficiency 1.
The low MCHC (31.0 g/dL) is unusual in macrocytic anemia and may reflect laboratory artifact or coexisting pathology 1.
Elevated RDW with macrocytosis in elderly patients carries particularly poor prognosis, with hazard ratios for mortality reaching 5.22 in non-anemic patients and remaining elevated even with anemia 2.
Renal Dysfunction Context
Stage 3b CKD (eGFR 33 mL/min/1.73 m²) is a critical finding because anemia prevalence increases dramatically when GFR falls below 30 mL/min/1.73 m², and CKD itself becomes a likely primary cause of anemia at this level 1.
However, anemia of CKD is typically normocytic and normochromic, not macrocytic, indicating that CKD alone does not explain this patient's presentation 1.
The combination of macrocytosis with CKD suggests multiple contributing etiologies requiring systematic evaluation 1.
Algorithmic Diagnostic Approach
Step 1: Immediate Laboratory Evaluation
Order the following tests immediately:
Vitamin B12 and folate levels to evaluate for megaloblastic anemia, the most common cause of macrocytic anemia (38.4% of cases) 1, 3.
Reticulocyte count (corrected for anemia/reticulocyte index) to distinguish between decreased RBC production versus increased destruction or loss 1.
Peripheral blood smear review to assess RBC morphology, identify hypersegmented neutrophils (megaloblastic), and evaluate for dysplastic features suggesting MDS 1.
Iron studies (serum ferritin, transferrin saturation, serum iron, TIBC) because iron deficiency can coexist and must be evaluated differently in CKD patients 1.
Thyroid-stimulating hormone (TSH) to exclude hypothyroidism as a contributing cause 1, 4.
Liver function tests (already available showing normal values, which helps exclude liver disease as primary cause) 1.
Step 2: Interpret Iron Studies in CKD Context
Critical caveat: Iron deficiency assessment differs in CKD patients 1:
In predialysis CKD, absolute iron deficiency is defined as transferrin saturation ≤20% with ferritin ≤100 μg/L (not the general population cutoffs of <15% and <30 ng/mL) 1.
Ferritin acts as an acute-phase reactant and may be falsely elevated in inflammation, making transferrin saturation more reliable in CKD 1.
If iron deficiency is confirmed in non-dialysis CKD without obvious blood loss, evaluate for gastrointestinal bleeding with stool guaiac testing and consider GI endoscopy 1.
Step 3: Determine Need for Bone Marrow Evaluation
Proceed to bone marrow biopsy if:
Two or more cell lines are abnormal (this patient has anemia + thrombocytopenia), which strongly suggests bone marrow pathology requiring hematology consultation 1.
MCV >110 fL significantly increases likelihood of megaloblastic anemia, but values between 100-110 fL require careful evaluation for MDS, especially in elderly patients 1, 3, 5.
No response to vitamin replacement therapy after 8-12 weeks suggests MDS rather than nutritional deficiency 1, 3.
MDS is the leading cause of macrocytic anemia in hematology clinics (19.3% of cases), followed by suspected bone marrow failure syndromes (11.8%) 5.
Step 4: Age-Specific Considerations
In this 73-year-old patient:
Bone marrow failure syndromes and myeloid malignancies are increasingly common causes of macrocytic anemia in elderly patients 4, 5, 6.
The combination of macrocytosis, thrombocytopenia, and advanced age creates high pretest probability for MDS, which requires bone marrow examination for definitive diagnosis 1, 5.
Multiple contributing causes are more likely in elderly patients, including poor nutrition, reduced absorption, medication effects, and chronic disease 1, 7.
Management Algorithm
If Vitamin B12/Folate Deficiency Confirmed:
Initiate vitamin B12 replacement (typically 1000 μg IM weekly for 4-8 weeks, then monthly) if B12 <200 pg/mL 1.
Folate supplementation (1-5 mg daily orally) if folate deficiency identified 1.
Never give folate alone without checking B12, as this can mask B12 deficiency while allowing neurologic damage to progress 1.
Reassess CBC in 8-12 weeks to confirm response; lack of improvement mandates bone marrow evaluation 1, 3.
If MDS Suspected or Confirmed:
Hematology referral is mandatory for risk stratification and treatment planning 1, 4.
For lower-risk MDS, erythropoiesis-stimulating agents (ESAs) at high doses (30,000-80,000 units EPO weekly or 150-300 μg darbepoetin weekly) can achieve 60% erythroid response rates when baseline EPO is low 1.
Lenalidomide is effective for MDS with del(5q), achieving 60-65% response rates 1.
Three patients with megaloblastic marrow who failed vitamin replacement were ultimately diagnosed with MDS, highlighting the importance of follow-up 1.
CKD-Specific Anemia Management:
Do not initiate ESA therapy yet because:
The macrocytic pattern suggests causes other than erythropoietin deficiency, which must be addressed first 1, 8, 9.
Correct iron deficiency and nutritional deficiencies before considering ESAs 1, 8, 9.
ESAs are indicated when hemoglobin falls below target ranges (typically <10 g/dL) after excluding and treating other causes 1, 8, 9.
The 2026 KDIGO guidelines emphasize comprehensive evaluation at diagnosis to identify additional causes beyond erythropoietin insufficiency, with individualized timing of treatment 8, 9.
Iron Replacement in CKD:
Oral iron may be tried first in predialysis CKD patients 1.
Intravenous iron is preferred if oral iron is not tolerated, ineffective, or if functional iron deficiency is present 1.
The 2026 KDIGO guidelines introduce more proactive thresholds for IV iron, especially in hemodialysis patients 8, 9.
Critical Pitfalls to Avoid
Do not attribute macrocytic anemia solely to CKD without investigating other causes, as CKD typically causes normocytic anemia 1.
Do not delay bone marrow biopsy when bicytopenia is present, as this pattern strongly suggests primary bone marrow pathology 1.
Do not use general population iron deficiency cutoffs in CKD patients; use CKD-specific thresholds 1.
Do not overlook GI malignancy in elderly patients with iron deficiency and CKD; the prevalence of dual pathology is high, strengthening the case for upper and lower GI tract evaluation 1.
Do not miss the multiplicative mortality risk of elevated RDW plus macrocytosis in elderly patients, which should prompt thorough evaluation and close follow-up 2.